The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Evaluation of Verapamil Efficacy in Peyronie’S Disease Comparing With Pentoxifylline
Open accessAbstract
INTRODUCTION: Peyronie's disease described as penile curvature, fibromathosis and pain that occur most often in men aged 40 to 60 years. The main complaint that caused the patient to visit the clinic is nodules on the upper surface of the penis, causing curvature and distortion particularly during erection, but they don't have any urinary problem. In this study, we evaluated the effect of verapamil compared to pentoxifylline in Peyronie's disease. METHODS: In this study, 90 patients with signs and symptoms of Peyronie's disease which were diagnosed and were in the age range 40 to 70 years enrolled. The patients were randomly divided into 3 groups. First group received pentoxifylline orally at a dose of 400 mg three times a day, in the second group verapamil (10 mg every other week for up to 12 sessions) was injected into the lesion and the third group received both treatments in combination. RESULTS: In patients, who received pentoxifylline, curvature reduction was 26.7%, plaque size reduction was 30%, the recovery rate of erectile dysfunction was 46.7% and pain reduced was 73.3%. Each of these cases in patients, who used beta-blockers, was 36.7%, 33.3%, 66.7% and 76.6%. In combination therapy, curvature reduction was 36.7%, plaque size reduction was 33.3%, the recovery rate of erectile dysfunction was 86.7% and pain reduced was 80%. CONCLUSION: In our study there was no significant difference between two groups using verapamil or pentoxifylline, but there was a significant improvement in combination therapy group. Due to our results we propose that combination therapy can improve results and should be considered as a choice in treatment of Peyronie's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R., & Lue, T. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64223-x · Cited by 250
Gonzalez-Cadavid, N. F. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01195.x · Cited by 172 · cited 2×
“Peyronie’s disease with two definitions of fibromatos and penile curvature and erectile dysfunction mostly occur in men aged 40 to 60 (Gonzalez-Cadavid, 2009), but like any other disease in the area of empirical sciences exceptionally analyzed and reported in younger men (De Young & Bella, 2010).”
BackgroundMulhall, J. P., Nicholson, B., Pierpaoli, S., Lubrano, T., & Shankey, T. V. (2004) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3901170 · Cited by 43 · cited 1×
“(Mulhall et al., 2005) And pentoxifylline may reduce collagen synthesis (Lin, 2004).”
Background
Cited by
Evidence-Based Management Guidelines on Peyronie's Disease
Chung, E., Ralph, D., Kagioglu, A., Garaffa, G., Shamsodini, A., Bivalacqua, T., Glina, S., Hakim, L., Sadeghi-Nejad, H., & Broderick, G. (2016) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2016.04.062 · Cited by 227
Paulis, G., Romano, G., Paulis, L., & Barletta, D. (2017) · Advances in Urology · doi:10.1155/2017/4653512 · Cited by 44
“Even in this study, PTX appeared effective in treating PD [88].”
BackgroundPaulis, G., De Giorgio, G., & Paulis, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415969 · Cited by 21
Non-surgical therapies for Peyronie’s disease
Rosenberg, J. E., Ergun, O., Hwang, E. C., Risk, M. C., Jung, J. H., Edwards, M. E., Blair, Y., & Dahm, P. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012206.pub2 · Cited by 14
KARAKOSE, A., & YİTGİN, Y. (2024) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.23.05458-7 · Cited by 11
Metadata
- Authors
- Alizadeh, M., Karimi, F., & Fallah, M. R.
- Venue
- Global Journal of Health Science
- Published
- 2014-09-18
- Volume
- 6
- Issue
- 7
- Pages
- 23-30
- ISSN
- 1916-9736 (ISSN-L)
- 1916-9744
- OpenAlex
- W2147825221
- Cited by
- 40
- References
- 3
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of Verapamil Efficacy in Peyronie’S Disease Comparing With Pentoxifylline. https://app.cochat.ai/papers/10.5539/gjhs.v6n7p23
- The paper
- Alizadeh, M., Karimi, F., & Fallah, M. R. (2014). Evaluation of Verapamil Efficacy in Peyronie’S Disease Comparing With Pentoxifylline. Global Journal of Health Science. https://doi.org/10.5539/gjhs.v6n7p23
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.